Dexamethasone punctal plug - Ocular Therapeutix

Drug Profile

Dexamethasone punctal plug - Ocular Therapeutix

Alternative Names: Dexamethasone intracanalicular plug; Dexamethasone punctum plug; Dextenza; OTX-DP

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Ocular Therapeutix
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Ocular pain
  • Phase III Allergic conjunctivitis; Ocular inflammation
  • Phase II Dry eyes

Most Recent Events

  • 11 May 2017 Efficacy and adverse event data from pooled analysis of three phase III trials in Ocular inflammation and Ocular pain released by Ocular Therapeutix
  • 24 Feb 2017 Planned Prescription Drug User Fee Act (PDUFA) date for Ocular pain in USA (Ophthalmic) is 2017-07-19
  • 23 Feb 2017 US FDA accepts a resubmitted NDA for dexamethasone punctal plug for Ocular pain for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top